Know Cancer

or
forgot password

Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer


N/A
21 Years
N/A
Open (Enrolling)
Female
Women at Increased Risk for Developing Breast Carcinoma

Thank you

Trial Information

Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer


Inclusion Criteria:



- Women considered at increased risk for developing breast carcinoma (those with a
lifetime risk of >15%due to family history, genetic predisposition, prior radiation
therapy to the chest, prior biopsy showing a high risk lesion, or personal history of
breast cancer) that are being screened with breast MRI.

- Women who have a screening digital mammogram on the day of CESM or within 365 days
prior

Exclusion Criteria:

- Women under 21.

- Pregnant or possibly pregnant.

- Women who have a contraindication to the intravenous use of iodinated or
gadolinium-chelated contrast agent (i.e., allergy to either agent or severely
impaired renal function with a creatinine level > or = to 1.3).

- Women with breast implants.

- Women with pacemakers.

- Women with aneurysm clips that don't allow for MRI.

- Women too claustrophobic to undergo MRI.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic

Outcome Measure:

compare the sensitivity and specificity CESM

Outcome Description:

CESM to that of breast MRI in a population of women who are being screened because they are at increased risk for developing breast cancer. For this purpose a positive CESM test will be defined as a score of 4 or 5. We will use the existing MRI BIRADS system to score CESM images based on the characteristics of individual lesions and increased enhancement compared to the background. A positive MRI test will be defined by a BIRADs score of 4 or 5.

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Maxine Jochelson, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

12-214

NCT ID:

NCT01716247

Start Date:

October 2012

Completion Date:

October 2014

Related Keywords:

  • Women at Increased Risk for Developing Breast Carcinoma
  • Mammography (CESM)
  • MRI
  • Breast screening
  • 12-214
  • Breast Neoplasms
  • Carcinoma

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021